

AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior listings and versions of claims in the application.

CLAIMS

1. (currently amended) A method of identifying individuals having a polymorphism, comprising;
 - a. providing nucleic acid from a subject; and
 - b. detecting the presence of at least one polymorphism in said nucleic acid, said at least one polymorphism selected from the group consisting of polymorphisms found in SEQ ID Nos: ~~1-3360 and 3361-7669~~ 7063, 7064, 7071, 7073, and 7074.
2. (original) The method of Claim 1, further comprising step c) providing a prognosis to said subject based on the presence or absence of said at least one polymorphism.
3. (original) The method of Claim 2, wherein said prognosis comprises a genotype relative risk.
4. (original) The method of Claim 2, wherein said prognosis comprises a population attributable risk.
5. (original) The method of Claim 1, wherein said detecting step comprises use of a hybridization assay.
6. (original) The method of Claim 1, wherein said detecting step comprises use of a TAQMAN assay.

7. (original) The method of Claim 1, wherein said detecting step comprises use of an invasive cleavage assay.

8. (original) The method of Claim 1, wherein said detecting step comprises use of mass spectroscopy.

9. (original) The method of Claim 1, wherein said detecting step comprises use of a microarray.

10. (original) The method of Claim 1, wherein said detecting step comprises use of a polymerase chain reaction.

11. (original) The method of Claim 1, wherein said detecting step comprises use of a rolling circle extension assay.

12. (original) The method of Claim 1, wherein said detecting step comprises use of a sequencing assay.

13. (original) The method of Claim 1, wherein said detecting step comprises use of a hybridization assay employing a probe complementary to a polymorphism.

14. (original) The method of Claim 1, wherein said detecting step comprises use of a bead array assay.

15. (original) The method of Claim 1, wherein said detecting step comprises use of a primer extension assay.

16. (original) The method of Claim 1, wherein said detecting step comprises use of an enzyme mismatch cleavage assay.

17. (original) The method of Claim 1, wherein said detecting step comprises use of a branched hybridization assay.

18. (original) The method of Claim 1, wherein said detecting step comprises use of a NASBA assay.

19. (original) The method of Claim 1, wherein said detecting step comprises use of a molecular beacon assay.

20. (original) The method of Claim 1, wherein said detecting step comprises use of a cycling probe assay.

21. (original) The method of Claim 1, wherein said detecting step comprises use of a ligase chain reaction assay.

22. (original) The method of Claim 1, wherein said detection step comprises use of a sandwich hybridization assay.

23-36. (canceled)

37. (currently amended) A method for screening subjects for genetic markers associated with drug metabolizing enzyme(s), comprising:

- a) providing a biological sample comprising a nucleic acid from a subject;
- b) testing said nucleic acid for a polymorphism in a genetic marker associated with a drug metabolizing enzyme, said genetic marker comprising one or more nucleotide polymorphisms designated by n, said n selected from a base substitution, an insertion, or a deletion found in a sequence selected from the group consisting of SEQ ID Nos: ~~1-3360 and 3361-7669~~ 7063, 7064, 7071, 7073, and 7074.

38. (original) The method of Claim 37, wherein said biological sample is selected from the group consisting of blood, saliva, amniotic fluid, and tissue.

39. (original) The method of Claim 37, wherein said subject is a human.

40. (original) The method of Claim 37, wherein said nucleic acid comprises DNA.

41. (original) The method of Claim 37, wherein said nucleic acid comprises RNA.

42-75. (canceled)

76. (currently amended) A method of prescribing a drug to or treatment protocol for a subject, comprising;

- a. providing nucleic acid from said subject;
- b. using a detection assay to detect the presence of at least one polymorphism in said nucleic acid, said at least one polymorphism selected from the group consisting of polymorphisms found in SEQ ID Nos: ~~1-3360 and 3361-7669~~ 7063, 7064, 7071, 7073, and 7074; and,
- c. prescribing said drug or treatment protocol based upon the result of said detection assay.

77. (original) The method of Claim 76, further comprising step d) providing a prognosis to said subject based on the presence or absence of said at least one polymorphism.

78. (original) The method of Claim 77, wherein said prognosis comprises a genotype relative risk.

79. (original) The method of Claim 77, wherein said prognosis comprises a population attributable risk.

80. (original) The method of Claim 76, wherein said detection assay comprises a hybridization assay.

81. (original) The method of Claim 76, wherein said detection assay comprises a TAQMAN assay.

82. (original) The method of Claim 76, wherein said detection assay comprises an invasive cleavage assay.

83. (original) The method of Claim 76, wherein said detection assay comprises mass spectroscopy.

84. (original) The method of Claim 76, wherein said detection assay comprises a microarray.

85. (original) The method of Claim 76, wherein said detection assay comprises a polymerase chain reaction.

86. (original) The method of Claim 76, wherein said detection assay comprises a rolling circle extension assay.

87. (original) The method of Claim 76, wherein said detection assay comprises a sequencing assay.

88. (original) The method of Claim 76, wherein said detection assay comprises a hybridization assay employing a probe complementary to a polymorphism.

89. (original) The method of Claim 76, wherein said detection assay comprises a bead array assay.
90. (original) The method of Claim 76, wherein said detection assay comprises a primer extension assay.
91. (original) The method of Claim 76, wherein said detection assay comprises an enzyme mismatch cleavage assay.
92. (original) The method of Claim 76, wherein said detection assay comprises a branched hybridization assay.
93. (original) The method of Claim 76, wherein said detection assay comprises a NASBA assay.
94. (original) The method of Claim 76, wherein said detection assay comprises a molecular beacon assay.
95. (original) The method of Claim 76, wherein said detection assay comprises a cycling probe assay.
96. (original) The method of Claim 76, wherein said detection assay comprises a ligase chain reaction assay.
97. (original) The method of Claim 76, wherein said detection step comprises a sandwich hybridization assay.
98. (currently amended) The method of Claim 76, in which said detection assay comprises a kit for detecting a polymorphism, said kit comprising at least one reagent that specifically detects a polymorphism in a sequence selected from the group consisting of SEQ ID Nos: ~~1-3360 and 3361-7669~~ 7063, 7064, 7071, 7073, and 7074.

99. (original) The method of Claim 98, further comprising instructions for determining whether the subject is at increased risk of having a drug metabolism disorder.

100. (original) The method of Claim 99, wherein said at least one reagent comprises a nucleic acid probe.

101. (original) The method of Claim 98, wherein said kit comprises an in vitro diagnostic detection assay.

102. (original) The method of Claim 98, wherein said kit comprises an analyte specific reagent detection assay.

103. (original) The method of Claim 98, wherein said kit comprises a research-use-only detection assay.

104. (original) The method of Claim 76, wherein said nucleic acid is obtained from a biological sample, said sample being selected from the group consisting of blood, saliva, amniotic fluid, and tissue.

105. (original) The method of Claim 104, wherein said subject is a human.

106. (original) The method of Claim 104, wherein said nucleic acid comprises DNA.

107. (original) The method of Claim 104, wherein said nucleic acid comprises RNA.

108. (original) The method of Claim 104, wherein said kit comprises PCR primers.

109. (currently amended) The method of claim 98, in which said kit comprises an array of detection assays, said array comprising a plurality of drug metabolizing enzyme nucleotide polymorphism detection assays, one or more of said detection assays being capable of detecting one or more nucleotide polymorphisms designated by n in SEQ ID Nos: ~~1-3360 and 3361-7669~~ 7063, 7064, 7071, 7073, and 7074, wherein n represents a base substitution, insertion, or deletion compared to a wild-type sequence.

110. (original) The method of Claim 109, wherein said detection assay is selected from the group consisting of a sequencing assay, a polymerase chain reaction assay, a hybridization assay, a hybridization assay employing a probe complementary to a polymorphism, a microarray assay, a bead array assay, a primer extension assay, an enzyme mismatch cleavage assay, a branched hybridization assay, a rolling circle replication assay, a NASBA assay, a molecular beacon assay, a cycling probe assay, a ligase chain reaction assay, and a sandwich hybridization assay.

111-123. (canceled)